Clinical Advisory Board

Our Clinical Advisory Board, chaired by Frank Chinegwundoh MBE, consists of specialists who advise us on our clinical  agenda. They are:

Prof Frank Chinegwundoh MBE  MBBS MS MML FRCS(Eng) FRCS(Ed) FRCS(Urol) FEBU

I completed my medical degree at St George’s University Hospital, London.  After 12 years of training in various establishments in the UK and USA, I was appointed as a Consultant Urological Surgeon in 1996.  Along the way I obtained a Master of Surgery degree by thesis. As a consultant I have undertaken further training in Seattle to be able to offer low dose rate brachytherapy at Barts Health NHS Trust.

In 2008 I received a National award for clinical excellence, which was renewed in 2013.  I completed my Masters in Medical Law (MML) from Glasgow University in 2010.

I was the first to demonstrate that black men in the UK have a three-fold risk of prostate cancer (2006). My main research interest is in prostate cancer and ethnicity, which has led to international lecturing opportunities.

I am on the selection panel for medical students at Barts and for postgraduates examine MD(research) theses.  Other commitments include serving on various Department of Health (DH) committees including the prostate cancer advisory group, national cancer equalities initiative, bowel cancer screening advisory committee amongst others and was a member of the  cancer reform strategy board.

Since 1998 I have been executive chairman of the charity Cancer Black Care.  In 2013 my services to the NHS were recognized with an MBE and in 2015 I was confirmed as Honorary Visiting Professor at City University London, in the School of Health Sciences.


Chris Booth MBBS, FRCS

I qualified from St Bartholomew’s Hospital in 1969 and trained in Urology at the Institute of Urology, the Middlesex Hospital and Dublin, winning the BAUS Travelling Fellowship for clinical research.

From 1984-2006 I was lead urologist at Colchester General Hospital, achieving Regional Urology Cancer Centre accreditation in 2006.  During this time the department was heavily involved in trial work, clinical research and service redesign, becoming a DoH pilot site for the Cancer Services Collaborative, Action On Urology and the Informed Decision Making programmes.  These led to my drafting the urology chapters for the DoH’s reports on Shifting Care Closer to Home and World Class Commissioning.

Since 2006 I have worked independently, providing urological consultancy in the East of England, for Tower Hamlets PCT and for the Greater Manchester Clinical Assessment & Treatment Service.  I have just established the NHS Alliance’s Specialist Urology Group, am a Director of Healthwatch Essex and the Clinical Director for the Men’s Health Charity CHAPS.

I have, on occasion, been a Visiting Professor at Essex University, an Honorary Professor at City University and sometimes play golf.


Prof Nick James BSc (Hons) MBBS PhD FRCP FRCR

I am Founding Director of the University of Warwick Cancer Research Centre and Consultant in Clinical Oncology at the Queen Elizabeth Hospital Birmingham. I was previously Professor of Clinical Oncology at the University of Birmingham until my move to Warwick in 2013. I qualified in 1983 from St Bartholomew’s with the principal class medical prize and a First in Immunology. I undertook postgraduate training in London, Brussels and Tokyo as well as a PhD at Imperial College, London.

I co-founded the leading website CancerHelp UK in 1994. The website was one of the first to focus exclusively on patient information and was underpinned by a programme of educational research. It featured the first searchable database of clinical trials for patients seeking to enter a study. In 2002 it became the main patient resource on the Cancer Research UK website until being recently absorbed into their main site.

In the prostate cancer field, I led the first UK trial of gene therapy in prostate cancer and was UK chief investigator on the TAX327, which led to the licensing of docetaxel for prostate cancer. I have subsequently led a range of trials in prostate cancer most notably the STAMPEDE trial. This novel multi-arm multi-stage trial has formed a platform for testing, in parallel, a range of different therapies and has now recruited over 7000 men. The recent analysis of the docetaxel data from this study has demonstrated that use of docetaxel at diagnosis of advanced disease improves overall survival by over 20%.

In the bladder cancer field, I have led a series of trials of chemoradiotherapy for bladder cancer culminating in the phase III BC2001 trial, published in the New England Journal of Medicine in 2012 with an accompanying editorial describing the work as “ground-breaking” and “practice changing”.


Prof Stephen Langley MBBS(Hons) MS FRCS Urol

I am a Consultant Urological Surgeon at the RoyalSurreyCountyHospital and the St Luke’s Cancer Centre in Guildford.  I became a Consultant in 1998 and then after 6 years was appointed as Professor of Urology at the PostGraduate MedicalSchool of the University of Surrey, where I co-lead a major research programme in the field of prostate cancer.

I was educated at St Paul’s School London before studying medicine at St Bartholomew’s Medical School, London. I graduated with honours in 1988 and then began my surgical training.  In 1996 I passed my Specialist Consultant exams in Urology in which I was awarded the Keith Yates Gold medal for outstanding performance.

I have an international reputation as an expert in the diagnosis and treatment of early prostate cancer. In 1999 I pioneered the treatment of early prostate cancer by brachytherapy in the UK. This technique uses tiny radioactive seeds implanted into the prostate gland which treats the prostate cancer sparing the surrounding tissue.  To date I and my large team have successfully treated over 3000 men with this treatment.  The excellent clinical results have been widely published and presented.

In 2012 I published and presented the technique of 4D Brachytherapy, a novel method to perform prostate brachytherapy using both stranded and loose seeds in a one-stage procedure with real-time dosimetry.  This technique delivers an improved radiation dose to the prostate whilst reducing the side effects compared to earlier techniques. 4D Brachytherapy is quick to perform, reducing the anaesthetic time and allowing patients a quicker recovery.

My passion to improve the care for prostate cancer patients led me in 2003 to invent the technique of prostate template biopsy. This new method allows the surgeon to diagnose and monitor cancerous changes within the prostate in a more detailed and specific way. This technique, developed in Guildford, has been NICE approved and is now used throughout Europe.

I am a pioneering clinician and in recent years have trained as a robotic surgeon.  I use a Da Vinci robot to surgically remove cancerous prostate glands from patients as another tool in my armamentarium to treat prostate cancer patients.

I am the Chairman of the UK Prostate Brachytherapy Advisory Group and sit on the Department of Health’s Prostate Cancer Advisory Group, influencing national policy.  In 2005 I received Karl Stortz Golden Cystoscope awarded from the British Association of Urological Surgeons for an outstanding contribution to British Urology.  In 2013 I received a Silver Clinical Excellence award.  I have recently spearheaded a successful campaign to raise £4m from Charitable and NHS funds to build a prestigious new Centre of Urology at the RoyalSurreyHospital due for completion in 2017.

I am married with a daughter.  My interests outside of medicine include rugby, boating and sailing. I am a qualified Yachtmaster and like to spend most of my spare time afloat in the Caribbean and Mediterranean waters.


Prof Heather Payne MBBS, FRCP, FRCR

I am a Consultant in Clinical Oncology at University College Hospital, London. I trained at St Mary's Hospital London and after qualifying spent time working in general medicine both in London and also in Haiti where conventional medicine was mixed with voodoo practices.

I returned to London to train as a Clinical Oncologist and during this time developed an interest in urological oncology. I now have a busy practice in a teaching hospital where I work within a multidisciplinary team. I am actively involved in clinical research in all these therapeutic areas and have pioneered a programme of High Dose Rate Brachytherapy for prostate cancer.

My current research interests also include hormone therapy, sensitisation of hormones and radiotherapy, predictive indices for bowel toxicity with radiotherapy, chemotherapy and quality of life and decision-making for men with prostate cancer.

I am Principal Investigator in a number of international multi-centre and local studies. I am a trustee of the Prostate Cancer Research Centre and the chairman of the British Uro-oncology Group (BUG). I am the oncology lead for the National Prostate Cancer Audit.



GP, Backwell & Nailsea Medical Group with specialist interest in Men’s Health and Urology

I trained in Urology in Taunton and became a Member of the Royal College of Surgeons in 1999. I then spent 3 years completing research into the impact of prostate cancer on the quality of life of men and their partners, and was awarded my MD thesis in 2003. In 2004 I switched to General Practice and am now a partner at Backwell & Nailsea Medical Group in North Somerset. I continue to work in Urology, providing a primary care diagnostic urology service to 3 CCGs, including a community based LUTS, Haematuria and raised PSA one-stop service. I was a member of the Guideline Development Group for the NICE 'Lower Urinary Tract Symptoms in men' Clinical Guideline, published in 2010. I am deputy editor of ‘Trends in Urology and Men’s Health’ and involved extensively in educating my fellow GPs about Urology, particularly through the Prostate Cancer UK Masterclasses. I am currently chair of the educational advisory group for Prostate Cancer UK.

In my ‘spare time’, I am a trustee of the Health Improvement Project Zanzibar– a small UK based charity which runs 2 district hospitals on the island of Zanzibar, providing essential healthcare for over 250,000 people.